MeSH term
Frequency | Condition_Probility | Animals | 33 | 0.0 |
Humans | 131 | 0.0 |
Adolescent | 4 | 0.0 |
Adult | 10 | 0.0 |
Aged | 13 | 0.0 |
Case-Control Studies | 6 | 0.0 |
Comparative Study | 6 | 0.0 |
Female | 19 | 0.0 |
Male | 17 | 0.0 |
Middle Aged | 13 | 0.0 |
Time Factors | 8 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Ataxia Telangiectasia/*genetics | 7 | 10.0 |
Cell Cycle Proteins/*metabolism | 11 | 3.0 |
Chromosome Breakage/*genetics | 7 | 13.0 |
Dose-Response Relationship, Radiation | 4 | 1.0 |
Histones/metabolism | 5 | 2.0 |
Neoplastic Syndromes, Hereditary/*genetics | 2 | 4.0 |
Nuclear Proteins/*metabolism | 13 | 1.0 |
Phosphorylation | 27 | 0.0 |
Protein Kinases/metabolism | 7 | 1.0 |
Protein p53/metabolism | 7 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 11 | 1.0 |
Radiation Tolerance/genetics | 5 | 10.0 |
Research Support, Non-U.S. Gov't | 91 | 0.0 |
S Phase/*physiology | 5 | 10.0 |
Syndrome | 24 | 1.0 |
Aged, 80 and over | 6 | 0.0 |
Alleles | 6 | 0.0 |
Cell Cycle Proteins/*genetics | 19 | 12.0 |
Chromosomes, Human, Pair 8/*genetics | 3 | 2.0 |
DNA Mutational Analysis | 7 | 0.0 |
Genes, Tumor Suppressor | 4 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Nuclear Proteins/*genetics | 15 | 2.0 |
BRCA1 Protein/genetics/metabolism | 2 | 15.0 |
BRCA2 Protein/genetics/metabolism | 2 | 40.0 |
DNA Repair/genetics | 4 | 2.0 |
Genes, BRCA1 | 2 | 1.0 |
Genotype | 4 | 0.0 |
*Germ-Line Mutation | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Cell Cycle Proteins/genetics | 8 | 8.0 |
DNA Repair/*genetics | 8 | 2.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Haplotypes | 2 | 0.0 |
Nuclear Proteins/genetics | 9 | 3.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Cell Cycle Proteins/genetics/metabolism | 5 | 7.0 |
*DNA Repair | 16 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 6 | 0.0 |
Exodeoxyribonucleases/genetics/metabolism | 3 | 50.0 |
*Nuclear Proteins | 12 | 0.0 |
*Saccharomyces cerevisiae Proteins | 14 | 1.0 |
Telomerase/metabolism | 3 | 5.0 |
*Telomere | 2 | 7.0 |
Telomeric Repeat Binding Protein 1 | 2 | 20.0 |
Mutation | 22 | 0.0 |
Protein-Serine-Threonine Kinases/genetics | 3 | 2.0 |
*Recombination, Genetic | 4 | 1.0 |
Ataxia Telangiectasia/genetics | 3 | 6.0 |
Cell Cycle Proteins/genetics/*physiology | 2 | 11.0 |
Cell Division | 2 | 0.0 |
Cells, Cultured | 14 | 0.0 |
G2 Phase | 5 | 3.0 |
Gamma Rays | 7 | 3.0 |
Mice | 20 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 49 | 0.0 |
Amino Acid Sequence | 15 | 0.0 |
DNA Damage/*physiology | 3 | 6.0 |
Models, Biological | 9 | 0.0 |
Molecular Sequence Data | 18 | 0.0 |
Radiation, Ionizing | 18 | 12.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 16 | 0.0 |
cdc25 Phosphatase/metabolism | 4 | 7.0 |
Cell Line | 31 | 0.0 |
*DNA Damage | 23 | 3.0 |
Nuclear Proteins/metabolism | 12 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 6 | 0.0 |
Base Sequence | 9 | 0.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
Dimerization | 2 | 0.0 |
Genetic Complementation Test | 7 | 1.0 |
Hela Cells | 13 | 0.0 |
DNA Replication/physiology | 2 | 6.0 |
Flow Cytometry | 2 | 0.0 |
Nuclear Proteins/genetics/metabolism | 4 | 2.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 2 | 5.0 |
Binding Sites | 10 | 0.0 |
Cell Cycle | 8 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Chromatin/metabolism | 6 | 2.0 |
DNA-Binding Proteins/metabolism | 12 | 0.0 |
Fungal Proteins/metabolism | 2 | 1.0 |
G1 Phase | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Protein Binding | 8 | 0.0 |
Transfection | 10 | 0.0 |
BRCA1 Protein/genetics/*metabolism | 2 | 5.0 |
DNA Damage/genetics | 4 | 9.0 |
Macromolecular Substances | 8 | 0.0 |
DNA Damage/physiology | 2 | 7.0 |
DNA Replication/radiation effects | 3 | 25.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Immunoblotting | 4 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Telomere/*physiology | 2 | 28.0 |
Ultraviolet Rays | 8 | 1.0 |
Child | 6 | 0.0 |
Chromosome Aberrations | 3 | 0.0 |
Genomic Instability | 2 | 12.0 |
Karyotyping | 2 | 0.0 |
Cell Cycle/physiology | 3 | 0.0 |
DNA Damage | 20 | 2.0 |
DNA Repair Enzymes/genetics/metabolism | 2 | 66.0 |
Cohort Studies | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
*DNA Replication | 6 | 2.0 |
DNA-Binding Proteins/*metabolism | 7 | 0.0 |
S Phase | 7 | 2.0 |
Signal Transduction | 9 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Cell Cycle Proteins/metabolism | 10 | 2.0 |
Gene Deletion | 4 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Mitosis | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 4 | 0.0 |
*Chromosome Aberrations | 5 | 0.0 |
Facies | 2 | 7.0 |
Infant, Newborn | 3 | 0.0 |
Nuclear Proteins/*genetics/metabolism | 4 | 3.0 |
Radiation Tolerance | 3 | 3.0 |
X-Rays | 4 | 3.0 |
Protein Structure, Tertiary | 10 | 0.0 |
BRCA1 Protein/*physiology | 2 | 9.0 |
Cell Line, Transformed | 8 | 0.0 |
Nuclear Proteins/physiology | 3 | 3.0 |
*Alleles | 2 | 0.0 |
Abnormalities, Multiple/*genetics | 3 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
Radiation Tolerance/*genetics | 4 | 7.0 |
DNA Primers | 2 | 0.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 3 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Adenosinetriphosphatase/genetics | 2 | 4.0 |
DNA Helicases/genetics | 2 | 9.0 |
*DNA Repair Enzymes | 10 | 10.0 |
Genes, BRCA1/genetics | 2 | 2.0 |
*Antigens, Nuclear | 4 | 2.0 |
*DNA Helicases | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Caffeine/pharmacology | 2 | 2.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Fibroblasts | 3 | 0.0 |
Mutation/genetics | 2 | 0.0 |
*Phosphoproteins | 3 | 2.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
*Endodeoxyribonucleases | 4 | 15.0 |
*Exodeoxyribonucleases | 4 | 17.0 |
Fungal Proteins/*metabolism | 3 | 3.0 |
Kinetics | 3 | 0.0 |
Protein Transport/radiation effects | 2 | 33.0 |
Histones/*metabolism | 4 | 3.0 |
Mice, Transgenic | 2 | 0.0 |
Cell Cycle Proteins/genetics/physiology | 2 | 16.0 |
Histones/chemistry | 2 | 11.0 |
Models, Genetic | 4 | 0.0 |
Phenotype | 7 | 0.0 |
Growth Disorders/genetics | 3 | 10.0 |
Immunologic Deficiency Syndromes/genetics | 2 | 11.0 |
Meiosis | 2 | 1.0 |
Microcephaly/*genetics | 4 | 23.0 |
BRCA1 Protein/metabolism | 2 | 5.0 |
Cloning, Molecular | 5 | 0.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
DNA/metabolism | 5 | 0.0 |
Mitomycin/pharmacology | 3 | 3.0 |
Recombination, Genetic | 5 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Nuclear Proteins/metabolism/*physiology | 2 | 6.0 |
Cell Survival | 4 | 0.0 |
DNA Repair | 17 | 2.0 |
Saccharomyces cerevisiae/metabolism | 2 | 1.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Molecular Weight | 3 | 0.0 |
Multiprotein Complexes | 3 | 6.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Chromosome Breakage | 5 | 6.0 |
Telomere/*metabolism | 3 | 11.0 |
*Chromosome Breakage | 5 | 13.0 |
Serine/metabolism | 5 | 1.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Nuclear Proteins/*genetics/physiology | 2 | 8.0 |
Poland/epidemiology | 4 | 7.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Phosphorylation/radiation effects | 5 | 16.0 |
DNA Replication | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 3 | 1.0 |
Acute Disease | 3 | 0.0 |
Fanconi Anemia/*complications/genetics/therapy | 2 | 100.0 |
Gene Therapy | 3 | 0.0 |
Histocompatibility Testing | 2 | 0.0 |
Leukemia, Myeloid/*complications/genetics/therapy | 2 | 100.0 |
Stem Cell Transplantation | 2 | 4.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
Antibiotics, Antineoplastic/pharmacology | 3 | 3.0 |
Apoptosis/physiology | 2 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Protein p53/genetics/metabolism | 3 | 3.0 |
Signal Transduction/physiology | 2 | 0.0 |
Caffeine/metabolism | 2 | 7.0 |
Cell Cycle/*physiology | 4 | 1.0 |
Cell Line, Tumor | 6 | 0.0 |
Epistasis, Genetic | 2 | 3.0 |
Cell Cycle/*genetics | 2 | 2.0 |
Exons/genetics | 4 | 0.0 |
Genes, Recessive/genetics | 2 | 2.0 |
Transcription Factors/genetics | 2 | 0.0 |
Cell Cycle/genetics/radiation effects | 2 | 22.0 |
Cell Cycle Proteins/*genetics/*metabolism | 2 | 13.0 |
DNA Damage/*genetics | 2 | 3.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Cell Cycle Proteins/physiology | 2 | 5.0 |
Chromosome Mapping | 3 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Conserved Sequence | 2 | 0.0 |
*Mutation | 6 | 0.0 |
Nuclear Proteins/*genetics/*metabolism | 2 | 5.0 |
Cell Cycle Proteins/*physiology | 5 | 9.0 |
DNA Helicases/*physiology | 2 | 50.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Melanoma/epidemiology/*genetics | 2 | 13.0 |
Pedigree | 5 | 0.0 |
Skin Neoplasms/epidemiology/*genetics | 2 | 14.0 |
Blotting, Western | 5 | 0.0 |
Hydroxyurea/pharmacology | 2 | 3.0 |
Cell Cycle Proteins/genetics/*metabolism/radiation effects | 2 | 100.0 |
DNA-Binding Proteins/genetics/metabolism | 4 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 2 | 1.0 |
Protein Transport | 2 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Introns/genetics | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Retinoblastoma Protein/genetics/metabolism | 2 | 5.0 |
G1 Phase/physiology | 2 | 2.0 |
Virus Replication | 2 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Ataxia Telangiectasia | 2 | 20.0 |
DNA-Binding Proteins/*chemistry/genetics/*metabolism | 2 | 3.0 |
Exonucleases/metabolism | 2 | 14.0 |
Models, Molecular | 2 | 0.0 |
Cell Nucleus/metabolism/radiation effects | 2 | 33.0 |
DNA Repair/*physiology | 4 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
Gene Frequency | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Loss of Heterozygosity | 4 | 0.0 |
Cell Cycle Proteins/*genetics/metabolism | 3 | 5.0 |
Cell Survival/radiation effects | 3 | 3.0 |
DNA Damage/drug effects | 2 | 4.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Zinostatin/*pharmacology | 2 | 66.0 |
*Gene Expression Regulation | 3 | 0.0 |
Etoposide/pharmacology | 2 | 1.0 |
Nuclear Proteins/*physiology | 3 | 2.0 |
Chromosomal Proteins, Non-Histone/*genetics/*metabolism | 3 | 42.0 |
Endodeoxyribonucleases/*metabolism | 2 | 11.0 |
Exodeoxyribonucleases/*metabolism | 2 | 14.0 |
Saccharomyces cerevisiae Proteins/*metabolism | 2 | 9.0 |
Schizosaccharomyces pombe Proteins/*genetics/*metabolism | 3 | 75.0 |
Endodeoxyribonucleases/genetics/metabolism | 2 | 40.0 |
Methyl Methanesulfonate/pharmacology | 2 | 5.0 |
Saccharomyces cerevisiae Proteins/genetics/metabolism | 2 | 5.0 |
Loss of Heterozygosity/genetics | 2 | 1.0 |
*DNA Damage/radiation effects | 2 | 20.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Exons | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Child, Preschool | 3 | 0.0 |
Genetic Screening | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Introns | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
DNA/genetics/metabolism/*radiation effects | 2 | 100.0 |
